Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
BACKGROUND: Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC). AIM: To evaluate effectiveness, safety and use of tofacitinib in daily practice. METHODS: UC patients initiating tofacitinib were prospectively enrolled in 15 hospitals in the Netherlands. Corticosteroid-free clinical remission (short clinical colitis activity index [SCCAI] ≤2), biochemical remission (faecal calprotectin level ≤250 µg/g), combined corticosteroid-free clinical and biochemical remission, predictors of remission, safety outcomes, treatment dose and effect on lipids were dete... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2020 |
Schlagwörter: | real world / tofacitinib / ulcerative colitis / Prospective Studies / Humans / Middle Aged / Antibodies / Monoclonal / Humanized/therapeutic use / Male / Pyrroles/therapeutic use / Treatment Outcome / Pyrimidines/therapeutic use / Crohn Disease/drug therapy / Tumor Necrosis Factor-alpha/antagonists & inhibitors / Piperidines/therapeutic use / Colitis / Ulcerative/drug therapy / Protein Kinase Inhibitors/therapeutic use / Adult / Female / Registries / Ustekinumab/therapeutic use / Netherlands/epidemiology / Gastroenterology / Pharmacology (medical) / Hepatology / Journal Article / Observational Study |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-29040227 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://dspace.library.uu.nl/handle/1874/439570 |